Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes.
Ten patients each with the nodular and ulcerative forms of cutaneous leishmaniasis were selected by clinical and pathological criteria. Capsule itraconazole was given in a daily dose of 4 mg per kg body weight (max. 200 mg) for 6 weeks. Six patients (60.0%) of the nodular and nine patients (90.0%) of the ulcerative subgroups were cured by strict clinical and parasitological criteria. No major adverse effects were noted. Review after 6 months revealed no recurrences. In another ten patients (control group) not receiving any drug, the lesions showed no significant change except for one patient demonstrating spontaneous remission. Thus, itraconazole has a promising antileishmanial potential in India.
Dogra
J
J
C.G.H.S., 'Shivashakti', C-11, Malviya Nagar, Jaipur 302 017, Rajasthan, India.
Aneja
N
N